^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TAK-186
i
Other names: TAK-186, MVC-101, MVC 101, TAK 186, MVC101, TAK186
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Takeda
Drug class:
EGFR inhibitor, CD3 agonist
Related drugs:
over1year
A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors (ESMO 2023)
Cytokine release syndrome will be reported by ASTCT consensus grading. Recruitment is ongoing.
Clinical • P1/2 data • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
TAK-186
over1year
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer (clinicaltrials.gov)
P1/2, N=228, Recruiting, Takeda | N=123 --> 228 | Trial completion date: Oct 2024 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Sep 2025
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
|
MSI-H/dMMR • PD-L1 negative
|
TAK-186
over2years
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia (clinicaltrials.gov)
P1, N=0, Withdrawn, Presage Biosciences | N=12 --> 0 | Trial completion date: Jul 2031 --> Jun 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2031 --> Jun 2022
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Opdivo (nivolumab) • TAK-186
over2years
A Study of MVC-101 (Also Known as TAK-186) in Adults With Advanced or Metastatic Cancer (clinicaltrials.gov)
P1/2, N=123, Recruiting, Takeda | N=68 --> 123
Enrollment change
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR expression • ALK rearrangement • RAS mutation
|
TAK-186
over2years
Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186. (PubMed, J Immunother Cancer)
The studies shown support the advancement of TAK-186, and the pursuit of additional COBRA TCEs for the treatment of solid tumors.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR positive
|
TAK-186
3years
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Presage Biosciences | Initiation date: Jul 2021 --> Oct 2021
Clinical • Trial initiation date
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Opdivo (nivolumab) • TAK-186
over3years
Phase 0 Australia Master Protocol for CIVO Intratumoural Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Presage Biosciences
Clinical • New P1 trial
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Opdivo (nivolumab) • TAK-186
over3years
A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer (clinicaltrials.gov)
P1/2, N=68, Recruiting, Maverick Therapeutics, Inc
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR expression • ALK rearrangement
|
TAK-186
Share via
